亚宝药业：2025年半年度报告

Core Insights - The company reported a revenue of 1,139,408,464.81 yuan for the first half of 2025 [2] - The net profit attributable to shareholders of the listed company was 174,397,240.67 yuan [2] Financial Performance - The revenue figure indicates a strong performance in the first half of 2025, reflecting the company's operational capabilities [2] - The net profit shows a positive financial outcome, contributing to shareholder value [2]